Metastasis accounts for the highest mortality rates in solid tumor cancer patients. However, research and development have neglected this most lethal characteristic and, instead, have concentrated on the hallmarks of cancer that make tumor cells highly proliferative and distinctive from nonmalignant cells. The concentration on invasion and metastasis can be one of the most meaningful advancements in cancer investigation. Importantly, metastasis-free survival (MFS) was recently approved by the Food and Drug Administration (FDA) as a novel primary endpoint in clinical trials and has been used to evaluate the prognosis of patients with nonmetastatic castration-resistant prostate cancer and soft tissue sarcoma. This new definition enables to shift the focus of research and development in cancer therapeutics toward metastasis and to change the emphasis from using tumor shrinkage as a benchmark for indicating the efficacy of treatment to using MFS as a more representative endpoint for antimetastatic drugs. This perspective outlines the possibility to use this novel endpoint in other solid cancers, and examples of large clinical trials are given in which MFS is defined as an endpoint and/or in which antimetastatic strategies are being examined. These advances now open the door for the rapid development of antimetastatic therapies, which could be used in combination with standard cytotoxic cancer therapies. With pioneer research on metastasis prevention on the rise and the underlying biomechanisms of tumor cell motility and invasion explored further than ever before, we believe an intensified focus on antimetastatic properties will shape this era of cancer translational research.

Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University Faculties of Charles University Průmyslová 595 252 42 Vestec u Prahy Czech Republic

Cell Migration and Invasion Laboratory The Azrieli Faculty of Medicine Bar Ilan University Safed 1311502 Israel

Laboratory of Cancer Cell Invasion Department of Cell Biology Charles University Viničná 7 128 44 Prague Czech Republic

Zobrazit více v PubMed

Fernandes M., Rosel D., Brabek J. Solid cancer: The new tumour spread endpoint opens novel opportunities. Br. J. Cancer. 2019;121:513–514. doi: 10.1038/s41416-019-0536-0. PubMed DOI PMC

Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 2000;100:57–70. doi: 10.1016/S0092-8674(00)81683-9. PubMed DOI

Meirson T., Gil-Henn H., Samson A.O. Invasion and metastasis: The elusive hallmark of cancer. Oncogene. 2020;39:2024–2026. doi: 10.1038/s41388-019-1110-1. PubMed DOI

Rosel D., Fernandes M., Sanz-Moreno V., Brabek J. Migrastatics: Redirecting R&D in Solid Cancer Towards Metastasis? Trends Cancer. 2019;5:755–756. PubMed

Gandalovičová A., Rosel D., Fernandes M., Vesely P., Heneberg P., Čermák V., Petruzelka L., Kumar S., Sanz-Moreno V., Brábek J. Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges. Trends Cancer. 2017;3:391–406. doi: 10.1016/j.trecan.2017.04.008. PubMed DOI PMC

Beaver J.A., Kluetz P.G., Pazdur R. Metastasis-free Survival—A New End Point in Prostate Cancer Trials. N. Engl. J. Med. 2018;378:2458–2460. doi: 10.1056/NEJMp1805966. PubMed DOI

Gagnon R., Alimohamed N.S., Batuyong E., Chow A., Lee-Ying R.M. Metastasis-free survival as a predictor of overall survival in non-metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2019;37:201. doi: 10.1200/JCO.2019.37.7_suppl.201. DOI

Illeron T., Le Guellec S., Chevreau C., Cabarrou B., Lesluyes T., Lodin S., Massoubre A., Mounier M., Poublanc M., Chibon F., et al. Value of perioperative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: Study protocol of the target selection phase III CHIC-STS trial. BMC Cancer. 2020;20:716. PubMed PMC

Harney A.S., Karagiannis G.S., Pignatelli J., Smith B.D., Kadioglu E., Wise S.C., Hood M.M., Kaufman M.D., Leary C.B., Lu W.-P., et al. The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2(Hi) Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors. Mol. Cancer Ther. 2017;16:2486–2501. doi: 10.1158/1535-7163.MCT-17-0241. PubMed DOI PMC

Karagiannis G.S., Pastoriza J.M., Wang Y., Harney A.S., Entenberg D., Pignatelli J., Sharma V.P., Xue E.A., Cheng E., D’Alfonso T.M., et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Sci. Transl. Med. 2017;9 doi: 10.1126/scitranslmed.aan0026. PubMed DOI PMC

Borriello L., Karagiannis G.S., Duran C.L., Coste A., Oktay M.H., Entenberg D., Condeelis J.S. The role of the tumor microenvironment in tumor cell intravasation and dissemination. Eur. J. Cell Biol. 2020;99:151098. doi: 10.1016/j.ejcb.2020.151098. PubMed DOI PMC

A Study of Rebastinib (DCC-2036) in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors. Drug: Rebastinib, Phase 1; Drug: Carboplatin, Phase 2. Began: 2 January 2019; Estimated End: 2022. [(accessed on 20 July 2021)]; Available online: https://clinicaltrials.gov/ct2/show/NCT03717415.

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Paclitaxel in Patients with Advanced or Metastatic Solid Tumors. Drug: Rebastinib, Phase 1; Drug: Paclitaxel, Phase 2. Began: 19 September 2018; Estimated End: 2021. [(accessed on 20 July 2021)]; Available online: https://clinicaltrials.gov/ct2/show/NCT03601897.

Rebastinib Plus Anti-Tubulin Therapy with Paclitaxel or Eribulin in Metastatic Breast Cancer. Drug: Rebastinib, Phase 1; Drug: Paclitaxel; Drug: Eribulin Mesylate. Began: July 2016; Estimated End: 2021. [(accessed on 20 July 2021)]; Available online: https://clinicaltrials.gov/ct2/show/NCT02824575.

Colorectal Metastasis Prevention International Trial 2 (COMPIT-2); Assaf-Harofeh Medical Center. Drug: Propranolol and Etodolac, Phase 2. Began: April 2019; Estimated End: 2027. [(accessed on 20 July 2021)]; Available online: https://clinicaltrials.gov/ct2/show/NCT03919461.

Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery (BC-PC); Assaf-Harofeh Medical Center. Drug: Propranolol and Etodolac, Phase 2. Began: November 2019; Estimated End: 2026. [(accessed on 20 July 2021)]; Available online: https://clinicaltrials.gov/ct2/show/NCT03838029.

Advanced Therapies for Liver Metastases. Began: November 2020; Estimated End: 2026. [(accessed on 20 July 2021)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04622423.

Pignatelli J., Goswami S., Jones J.G., Rohan T.E., Pieri E., Chen X., Adler E., Cox D., Maleki S., Bresnick A., et al. Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration. Sci. Signal. 2014;7:ra112. doi: 10.1126/scisignal.2005329. PubMed DOI PMC

Agarwal S., Gertler F.B., Balsamo M., Condeelis J.S., Camp R.L., Xue X., Lin J., Rohan T.E., Rimm D.L. Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. Breast Cancer Res. 2012;14:R124. doi: 10.1186/bcr3318. PubMed DOI PMC

Forse C.L., Agarwal S., Pinnaduwage D., Gertler F., Condeelis J.S., Lin J., Xue X., Johung K., Mulligan A.M., Rohan T.E., et al. Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer. BMC Cancer. 2015;15:483. doi: 10.1186/s12885-015-1468-6. PubMed DOI PMC

Weidmann M.D., Surve C.R., Eddy R.J., Chen X., Gertler F.B., Sharma V.P., Condeelis J.S. Mena(INV) dysregulates cortactin phosphorylation to promote invadopodium maturation. Sci. Rep. 2016;6:36142. doi: 10.1038/srep36142. PubMed DOI PMC

TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients with Operable Breast Cancer. Began: October 2018; Estimated End: 2022. [(accessed on 20 July 2021)]; Available online: https://clinicaltrials.gov/ct2/show/NCT03694756.

Synthesis and migrastatic activity of cytochalasin analogues lacking a macrocyclic moiety

Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer

Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging

The emerging role of microtubules in invasion plasticity